NCT05296603

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer Who Failed From First Line PD-(L)-1 Inhibitors: Multiple Cohorts Perspective Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 83 (estimated)
• Sponsor: Hunan Province Tumor Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to explore the efficacy and biomarker explanation of IBI-322 Plus Lenvatinib on extensive stage small cell lung cancer who failed from first line PD-(L)1 inhibitors.

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	IBI-322 Plus Lenvatinib	IBI322 is based on the "3+3" model, with a dose ascent starting from 10mg

Timeline

• Start date: 2021-12-03
• Primary completion: 2024-10-30
• Completion: 2025-12-25
• First posted: 2022-03-25
• Last updated: 2024-01-10

Locations

1 site across 1 country: China